Semaglutide 2.4 mg milestones from published trials (abstracts read November 8, 2026); different trials, so the rows are not one continuous curve
Point in treatmentWhat was measuredResultTrial
Weeks 0–16Dose escalation from 0.25 mg to 2.4 mgEscalation period; not a weight endpointWegovy label schedule
Week 20Mean weight change after run-in (16 weeks escalation, 4 weeks at 2.4 mg)−10.6%STEP-4 (JAMA, 2021)
Week 68Mean weight change, all randomized participants−14.9% vs −2.4% placeboSTEP-1 (NEJM, 2021)
Week 68Mean change in kilograms−15.3 kg vs −2.6 kg placeboSTEP-1
Week 20 to 68, stayed on drugFurther change after run-in−7.9%STEP-4
Week 20 to 68, switched to placeboChange after stopping+6.9%STEP-4
Week 72Mean change at maximum tolerated dose (1.7 or 2.4 mg)−13.7%SURMOUNT-5 (NEJM, 2025)

How fast does semaglutide work?

Slowly at first, by design. The first 16 weeks on the Wegovy label are spent climbing through lower doses, so the early months happen below the dose that produced the headline results.

The clearest early checkpoint comes from STEP-4. Its 902 participants all took semaglutide for 20 weeks before randomization, and the 803 who reached 2.4 mg had lost a mean 10.6% by then. That figure is for people who tolerated the full dose, so it flatters the average a little; STEP-4 randomized only those who got there.

What happens between week 20 and week 68?

Weight loss continues, but more slowly. In STEP-4, people who stayed on semaglutide lost a further mean 7.9% of their week-20 weight over the next 48 weeks. Compare that with the first 20 weeks and you can see the curve bending: roughly 10% in 20 weeks, then about 8% more over nearly a year.

STEP-1 shows where the average landed for the whole group at week 68: −14.9%, counting everyone randomized, including people who stopped the drug. The paper calls this its primary estimand, which assessed effects "regardless of treatment discontinuation or rescue interventions." That is a conservative way to count, and it is the number to use when comparing programs that quote trial results.

Who was in STEP-1?

The trial enrolled 1,961 adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition, and excluded people with diabetes. They were randomized two to one to semaglutide 2.4 mg or placebo for 68 weeks, and both groups received lifestyle intervention. The study was funded by Novo Nordisk, which makes Wegovy.

If you have type 2 diabetes, STEP-1 is not your benchmark, because it excluded you. The same goes for teenagers, who were studied separately, and for anyone taking semaglutide without the counseling both trial groups received. A trial average describes the people who were in the trial.

How many people reached 5%, 10% or 15%?

Averages hide the spread. STEP-1 reported the share of participants who crossed each threshold at week 68:

STEP-1 responders at week 68, per the NEJM abstract (2021), read November 8, 2026
Weight reductionSemaglutide 2.4 mgPlacebo
5% or more86.4%31.5%
10% or more69.1%12.0%
15% or more50.5%4.9%

Read the other side of the table too: about 1 in 7 people on semaglutide did not reach 5%, and about half did not reach 15%. A program that implies 15% is typical is quoting the middle of the distribution as a promise.

Why did the placebo group lose weight too?

Because placebo participants also got lifestyle counseling. They lost a mean 2.4% (2.6 kg) by week 68, and 31.5% of them lost at least 5%. The honest measure of the drug's effect is the difference between the groups: 12.4 percentage points, per the trial's estimated treatment difference.

The trial also reported greater improvement in cardiometabolic risk factors and in participant-reported physical functioning with semaglutide than with placebo. Those are group findings, measured at week 68, not week 8.

What happens if you stop semaglutide?

In STEP-4, weight came back. Participants switched to placebo at week 20 regained a mean 6.9% over the following 48 weeks, while those who continued lost 7.9% more. The gap between the groups was 14.8 percentage points.

That does not mean every person regains, and STEP-4 did not test tapering or other off-ramps. It does mean the trial evidence treats semaglutide as a long-term medicine, which matters for your budget as much as your plan. A 68-week trial result assumes 68 weeks of drug.

What should you track along the way?

Trials weigh participants at set visits, and a monthly weigh-in on the same scale, at the same time of day, gives you a comparable trend. Note your dose at each weigh-in, because loss in the escalation months happens at lower doses than the headline results. Bring the trend and any side effects to each prescriber visit; that is the information a dose decision rests on.

Does the 7.2 mg dose change the timeline?

Wegovy HD 7.2 mg is labeled for adults who have tolerated 2.4 mg for at least four weeks and need more weight reduction, so it extends the timeline rather than shortening it. We have not reviewed the 7.2 mg efficacy trials for this page, so we do not quote a weight result for it.

How should you read a timeline someone sells you?

Three questions keep marketing honest:

  1. Which trial and which week? A 68-week figure quoted beside a "3-month plan" is a mismatch.
  2. Which drug? STEP trials used branded semaglutide. Compounded semaglutide is not FDA-approved and has no trial results of its own.
  3. Which estimand? Results counting only people who stayed on the full dose run higher than results counting everyone.

Trials also paired the drug with lifestyle counseling for both groups, and STEP-1 excluded people with diabetes. For tirzepatide's equivalent curve, see our tirzepatide weight loss timeline; for the full STEP program, STEP trial results; and for what photos and testimonials leave out, semaglutide before and after. The GLP-1 myths vs facts page covers common timeline claims.

Frequently asked questions

How much weight can you lose on semaglutide in 3 months?

No trial on our list reports a 12-week endpoint, so we will not quote one. The nearest checkpoint is STEP-4's week 20, after 16 weeks of escalation and 4 weeks at 2.4 mg, where participants who reached the full dose had lost a mean 10.6%. Three months on the label schedule ends before you reach 2.4 mg.

When does semaglutide weight loss plateau?

The trials show slowing rather than a fixed plateau date. In STEP-4, the mean loss was 10.6% over the first 20 weeks and 7.9% more over the next 48 weeks among those who continued. STEP-1's group average reached 14.9% at week 68. Where your own curve flattens depends on dose, tolerance and many individual factors.

Do you regain weight after stopping semaglutide?

In STEP-4, people switched to placebo after 20 weeks on semaglutide regained a mean 6.9% of their week-20 weight over the next 48 weeks, while those who continued lost a further 7.9%. That is group evidence, not a rule for everyone, but it is why the trial evidence treats semaglutide as ongoing treatment rather than a short course.

Is the 14.9% STEP-1 result an average for everyone?

It is the mean change for all 1,961 randomized participants analyzed under the primary estimand, which counted people regardless of whether they stopped treatment or used rescue interventions. Half of semaglutide participants lost 15% or more, and 86.4% lost at least 5%. Participants had no diabetes and received lifestyle counseling alongside the drug.

Does compounded semaglutide follow the same timeline?

There is no trial evidence either way. Compounded semaglutide is not FDA-approved, is made with the drug in Wegovy but is not the same product, and has not been tested in trials like STEP-1. Doses and concentrations can differ between pharmacies, so the published timeline belongs to branded semaglutide only.

Sources

  1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989-1002 — abstract read 2026-11-08 (PubMed record); doi 10.1056/NEJMoa2032183
  2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 2021;325:1414-1425 — abstract read 2026-11-08 (PubMed record)
  3. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36 — abstract read 2026-11-08 (PubMed record)
  4. FDA label via DailyMed: Wegovy (semaglutide) prescribing information — revised 6/2026; escalation schedule and 7.2 mg criteria read 2026-11-08

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.